Study of rVWF for severe bleeding disorder in children
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 18 years old when they are screened.
- Your child has a confirmed diagnosis of severe von Willebrand disease (with low lab levels and specific vWD type).
- Your child has received von Willebrand factor (VWF) treatment for a set time (usually at least 12 months if age 2+), and either had breakthrough bleeds or a doctor recommends switching to this study treatment.
- Your child has reliable medical records showing bleeding events and treatment history for the required time period before joining.
- Your child’s body size falls within the study’s age-based weight/body-mass limits.
- If your child has started periods (or reached puberty), the pregnancy test at screening must be negative and they must use very effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
This Phase 3 trial tests an recombinant version of the von Willebrand factor (rVWF) for people with severe von Willebrand disease (VWD) living in China. It aims to see if the drug can safely control bleeding and help those who need regular clotting factor treatments.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
This study tests whether SR604, a new injection given under the skin, can reduce bleeding episodes in people with von Willebrand disease (a condition where blood doesn't clot properly). The trial will measure how well it works, how safe it is, and how your body processes it.
Hear when a new Von Willebrand Disease (VWD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.